Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T22:19:26.203Z.
Calculation as of: 2026-10-06T22:19:26.203Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3fd66fa07f89ff8c2236b8eda0ba832ed38a6b1a46891be7cbf8760d0061f77
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
XORTX Therapeutics Inc.
Market Cap
$481786.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$403887.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$378849.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$667469.00
Price/FCF Ratio
N/A
TTM Avg
837939.80
3Y Avg
5687342.72
5Y Avg
5687342.72
Market Cap
$824550.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XORTX Therapeutics Inc. (XRTX) | $481786.00 | N/A | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $667469.00 | N/A | 837939.80 | 5687342.72 | 5687342.72 |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $716854.00 | N/A | 0.46 | 0.46 | 0.46 |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A | 0.22 | 0.19 | 1.45 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
